Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?
Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
China Anti-Cancer Association
2023-12-01
|
| Series: | Cancer Biology & Medicine |
| Subjects: | |
| Online Access: | https://www.cancerbiomed.org/content/20/12/1035 |
| _version_ | 1797322897175347200 |
|---|---|
| author | Lin Ma Liufu Deng Jianfeng Peng Jinming Yu Xiangjiao Meng |
| author_facet | Lin Ma Liufu Deng Jianfeng Peng Jinming Yu Xiangjiao Meng |
| author_sort | Lin Ma |
| collection | DOAJ |
| description | Maintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials. |
| first_indexed | 2024-03-08T05:20:54Z |
| format | Article |
| id | doaj.art-5fe4afed98eb4d04b203a999fdfdcece |
| institution | Directory Open Access Journal |
| issn | 2095-3941 |
| language | English |
| last_indexed | 2024-03-08T05:20:54Z |
| publishDate | 2023-12-01 |
| publisher | China Anti-Cancer Association |
| record_format | Article |
| series | Cancer Biology & Medicine |
| spelling | doaj.art-5fe4afed98eb4d04b203a999fdfdcece2024-02-06T12:47:11ZengChina Anti-Cancer AssociationCancer Biology & Medicine2095-39412023-12-0120121035104610.20892/j.issn.2095-3941.2023.0402Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer?Lin Ma0Liufu Deng1Jianfeng Peng2Jinming Yu3Xiangjiao Meng4Department of Oncology, Renmin Hospital of Wuhan University, Wuhan 430000, ChinaSchool of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, ChinaDepartment of Oncology, Renmin Hospital of Wuhan University, Wuhan 430000, ChinaDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, ChinaMaintenance immunotherapy after concurrent chemoradiotherapy remains the standard therapeutic approach in patients with unresectable locally advanced non-small cell lung cancer (LA-NSCLC). The efficacy of pembrolizumab without chemotherapy in stage IV NSCLC has incited interest in similar approaches for LA-NSCLC. Several recent investigations involving the synergistic potential of immunotherapy combined with radiotherapy (iRT) have generated encouraging results. This review discusses the existing studies and prospective directions of chemotherapy-free iRT strategies in unresectable LA-NSCLC. Although the initial findings of chemotherapy-free iRT strategies have shown promising efficacy, we must consider the methodologic limitations of current studies and the myriad of challenges that accompany the implementation of chemotherapy-free iRT. These challenges include determining the optimal dose and fractionation, precise target volume delineation, and identification of additional suitable patient cohorts. Furthermore, the feasibility of chemotherapy-free iRT as a novel treatment modality for select patients with LA-NSCLC is contingent upon validation through randomized phase III trials.https://www.cancerbiomed.org/content/20/12/1035locally advanced non-small cell lung cancer (la-nsclc)radiotherapyimmunotherapynew regimenchallenges |
| spellingShingle | Lin Ma Liufu Deng Jianfeng Peng Jinming Yu Xiangjiao Meng Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? Cancer Biology & Medicine locally advanced non-small cell lung cancer (la-nsclc) radiotherapy immunotherapy new regimen challenges |
| title | Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? |
| title_full | Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? |
| title_fullStr | Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? |
| title_full_unstemmed | Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? |
| title_short | Chemotherapy-free radiotherapy combined with immune checkpoint inhibitors: a new regimen for locally advanced non-small cell lung cancer? |
| title_sort | chemotherapy free radiotherapy combined with immune checkpoint inhibitors a new regimen for locally advanced non small cell lung cancer |
| topic | locally advanced non-small cell lung cancer (la-nsclc) radiotherapy immunotherapy new regimen challenges |
| url | https://www.cancerbiomed.org/content/20/12/1035 |
| work_keys_str_mv | AT linma chemotherapyfreeradiotherapycombinedwithimmunecheckpointinhibitorsanewregimenforlocallyadvancednonsmallcelllungcancer AT liufudeng chemotherapyfreeradiotherapycombinedwithimmunecheckpointinhibitorsanewregimenforlocallyadvancednonsmallcelllungcancer AT jianfengpeng chemotherapyfreeradiotherapycombinedwithimmunecheckpointinhibitorsanewregimenforlocallyadvancednonsmallcelllungcancer AT jinmingyu chemotherapyfreeradiotherapycombinedwithimmunecheckpointinhibitorsanewregimenforlocallyadvancednonsmallcelllungcancer AT xiangjiaomeng chemotherapyfreeradiotherapycombinedwithimmunecheckpointinhibitorsanewregimenforlocallyadvancednonsmallcelllungcancer |